What's keeping less expensive versions of biologic drugs off the U.S. market?
April 19, 2014
5,670
39
0.69%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Amna Nawaz Episodes Around April 19, 2014
See what was published immediately before and after this episode.
9:57Now PlayingWhat's keeping less expensive versions of biologic drugs off the U.S. market?
YouTube Description
as posted by the channelWe look at a revolutionary class of drugs called "biologics." Americans have been paying more for their benefits than patients in Europe or Asia some say, because the "generic" versions or "biosimilars" have not hit the U.S. market. Dr. Emily Senay looks into why there's a delay and when American consumers can expect discounts.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.